Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis

Trial Profile

Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Lanreotide (Primary) ; Octreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 04 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
    • 28 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top